Skip to main content

Toxicity

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

GenFleet Therapeutics
GenFleet TherapeuticsChina - Shanghai
1 program
1
GFH312Phase 11 trial
Active Trials
NCT04676711Completed76Est. Oct 2022
Biocorp
BiocorpFrance - Issoire
1 program
Reduced radiation volumesN/A1 trial
Active Trials
NCT03975452Unknown52Est. Dec 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GenFleet TherapeuticsGFH312
BiocorpReduced radiation volumes

Clinical Trials (2)

Total enrollment: 128 patients across 2 trials

A Study of GFH312 in Healthy Subjects

Start: Apr 2021Est. completion: Oct 202276 patients
Phase 1Completed
NCT03975452BiocorpReduced radiation volumes

Volume De-escalation in Neoadjuvant Radiochemotherapy of Rectal Cancer

Start: Nov 2007Est. completion: Dec 201952 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.